Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Get Free Report) Director Kathryn Guarini sold 400 shares of the business’s stock in a transaction that occurred on Wednesday, September 2nd. The shares were sold at an average price of $850.00, for a total transaction of $340,000.00. Following the completion of the sale, the director directly owned 603 shares in the company, valued at approximately $512,550. This trade represents a 39.88% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Kathryn Guarini also recently made the following trade(s):
- On Monday, August 10th, Kathryn Guarini sold 400 shares of Regeneron Pharmaceuticals stock. The stock was sold at an average price of $800.00, for a total value of $320,000.00.
Regeneron Pharmaceuticals Price Performance
NASDAQ REGN traded down $8.56 during trading hours on Thursday, hitting $843.47. The company had a trading volume of 496,172 shares, compared to its average volume of 839,664. Regeneron Pharmaceuticals, Inc. has a 52 week low of $541.00 and a 52 week high of $859.34. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.78 and a current ratio of 3.34. The firm has a market capitalization of $86.84 billion, a price-to-earnings ratio of 20.85, a PEG ratio of 1.61 and a beta of 0.19. The firm has a 50 day simple moving average of $729.93 and a 200 day simple moving average of $719.06.
Regeneron Pharmaceuticals Announces Dividend
The company also recently disclosed a quarterly dividend, which was paid on Monday, August 31st. Stockholders of record on Tuesday, August 18th were given a dividend of $0.94 per share. The ex-dividend date was Tuesday, August 18th. This represents a $3.76 annualized dividend and a dividend yield of 0.4%. Regeneron Pharmaceuticals’s dividend payout ratio is 9.29%.
Analyst Upgrades and Downgrades
Several analysts have issued reports on the company. Benchmark raised Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and set a $185.00 target price for the company in a research note on Tuesday, July 7th. HSBC decreased their price target on shares of Regeneron Pharmaceuticals from $990.00 to $880.00 and set a “buy” rating on the stock in a research note on Monday, July 6th. Guggenheim upped their price objective on shares of Regeneron Pharmaceuticals from $1,000.00 to $1,030.00 and gave the company a “buy” rating in a research note on Monday, August 3rd. BMO Capital Markets reduced their target price on shares of Regeneron Pharmaceuticals from $900.00 to $730.00 and set an “outperform” rating on the stock in a report on Monday, May 18th. Finally, Royal Bank Of Canada lifted their target price on shares of Regeneron Pharmaceuticals from $696.00 to $737.00 and gave the stock a “sector perform” rating in a research report on Friday, July 31st. Fourteen equities research analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $800.36.
Read Our Latest Research Report on Regeneron Pharmaceuticals
Regeneron Pharmaceuticals News Roundup
Here are the key news stories impacting Regeneron Pharmaceuticals this week:
- Positive Sentiment: Regeneron reported completion of a Phase 1/2 study evaluating its cemiplimab (Libtayo) combination with SNS-101. The update advances a potential oncology program, although no new efficacy results were disclosed. Regeneron’s Cemiplimab Combo Trial With SNS-101 Reaches Completion
- Neutral Sentiment: A market report projects continued growth in the global complement-inhibitors market through 2035 and lists Regeneron among the major industry participants, supporting the company’s longer-term opportunity but offering no company-specific financial update. 2026 Complement Inhibitors Market Analysis Report
- Neutral Sentiment: Analysts remain moderately optimistic about REGN’s outlook, with coverage highlighting its recent outperformance versus the broader healthcare sector. Regeneron Pharmaceuticals Stock: Is REGN Outperforming the Healthcare Sector?
- Negative Sentiment: Multiple law firms are publicizing a securities class action focused on Regeneron’s Phase 3 Fianlimab-Libtayo melanoma trial. The lawsuit alleges that the company’s disclosures about slowing event accrual and the trial protocol understated the risk of failing the primary endpoint; the trial ultimately failed, undermining earlier positive trial-risk messaging. Investors who purchased shares during the alleged class period may seek lead-plaintiff status by September 14, 2026. Hagens Berman Regeneron Securities Fraud Class Action Alert
- Negative Sentiment: The repeated litigation announcements increase headline, financial and reputational risk for Regeneron Pharmaceuticals (REGN). The core concern is that the failed melanoma study could delay or reduce expectations for a key growth opportunity and expose the company to potential damages and legal costs. REGN Investors Securities Fraud Lawsuit Notice
Institutional Trading of Regeneron Pharmaceuticals
Several hedge funds and other institutional investors have recently bought and sold shares of REGN. Amundi boosted its stake in shares of Regeneron Pharmaceuticals by 0.4% during the second quarter. Amundi now owns 1,013,540 shares of the biopharmaceutical company’s stock valued at $631,983,000 after purchasing an additional 3,742 shares during the period. HighTower Advisors LLC increased its stake in shares of Regeneron Pharmaceuticals by 9.7% in the second quarter. HighTower Advisors LLC now owns 64,650 shares of the biopharmaceutical company’s stock worth $40,312,000 after buying an additional 5,725 shares during the period. Groupe la Francaise raised its holdings in Regeneron Pharmaceuticals by 25.1% during the 2nd quarter. Groupe la Francaise now owns 553 shares of the biopharmaceutical company’s stock valued at $321,000 after buying an additional 111 shares during the last quarter. VIRGINIA RETIREMENT SYSTEMS ET Al bought a new stake in Regeneron Pharmaceuticals during the 2nd quarter valued at $15,884,000. Finally, California State Teachers Retirement System boosted its position in Regeneron Pharmaceuticals by 63,274.2% during the 2nd quarter. California State Teachers Retirement System now owns 97,723,683 shares of the biopharmaceutical company’s stock valued at $60,934,625,000 after buying an additional 97,569,482 shares during the period. Institutional investors own 83.31% of the company’s stock.
Regeneron Pharmaceuticals Company Profile
Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.
Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.
Featured Stories
- Five stocks we like better than Regeneron Pharmaceuticals
- The Path to $230 Billion: Broadcom Outlines the Next Phase of Its AI Growth Story
- NVIDIA’s Hugging Face Deal Raises a Bigger Question About Its AI Moat Now
- Dropping the Dough: Yum! Brands Strategically Trims the Fat
- These 3 Stock Charts Just Flashed the Dreaded Death Cross Pattern
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
